Clinical trials: neoadjuvant therapy, completed
Breast Cancer
99mTc-3PRGD2 SPECT/CT in Breast Cancer Patients
This is an open-label SPECT/CT (single photon emission computed tomography / computed tomography) study to investigate clinical study of 99mTc-3PRGD2 SPECT/CT in diagnosis and efficacy evaluation of breast cancer.
- Trial name
- NCT02742168
- Testing
- 99mTc-3PRGD2
- Where
- China
- Volunteers
- 46 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Crohn's Disease
Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)
This 26-week extension study evaluates the efficacy and safety of certolizumab pegol administered subcutaneously every 4 weeks (dosed at Weeks 16, 20, 24, 28 and 32) in subjects with active Crohn's disease who had no clinical…
- Trial name
- NCT00329420
- Testing
- Certolizumab pegol
- Where
- 23 sites in Japan
- Volunteers
- 46 people
- Sponsor
- UCB Pharma
Non-Hodgkin's Lymphoma
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
About 60% of patients with DLBCL can be cured with a chemotherapy program. It is called RCHOP-21 (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone). It is given once every 3 weeks, for 18 weeks.
- Trial name
- NCT00712582
- Testing
- Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin, Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Cancer, Radiation Pneumonitis
Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology
Although recent global trends indicate reduced postoperative mortality after esophagectomy, major morbidity, in particular pulmonary, remains high, with considerable health and economic costs.
- Conditions
- Esophageal Cancer, Radiation Pneumonitis, Pulmonary Fibrosis, Respiratory Failure
- Trial name
- NCT03462524
- Testing
- Esophagectomy
- Where
- 2 sites in Ireland
- Volunteers
- 384 people
- Sponsor
- St. James's Hospital, Ireland
Locally Advanced Breast Cancer (LABC)
Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy
The objective of this pilot study is to determine the effectiveness of Fluorothymidine Positron Emission Tomography (FLT PET) and Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) in assessing tumour response to…
- Trial name
- IMPACT (NCT01240681)
- Testing
- FLT PET and BOLD MRI scan
- Where
- 4 sites in Canada
- Volunteers
- 32 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Fallopian Tube Cancer, Metastatic Cancer
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00993655
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 50 sites in United States, Canada and 2 more
- Volunteers
- 275 people
- Sponsor
- Canadian Cancer Trials Group
Lung Cancer
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00278148
- Testing
- carboplatin, Erlotinib, paclitaxel
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Nathan Pennell, MD, PhD
Breast Cancer
Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer
This study aimed to evaluate the feasibility of dual sentinel node staining method using mixture of indocyanine green(ICG) and radioisotope (RI) in breast cancer patients who receive neoadjuvant chemotherapy.
- Trial name
- NCT02168452
- Testing
- sentinel lymph node biopsy(SLNB)
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- National Cancer Center, Korea
Esophageal Cancer
PReoperative Identification Of Response to Neoadjuvant Chemoradiotherapy for Esophageal Cancer
Rationale: For resectable esophageal cancer the standard therapy is 5 weeks of neoadjuvant chemoradiotherapy (nCRT) followed by surgery 6-8 weeks afterwards.
- Trial name
- PRIOR (NCT02125448)
- Testing
- MRI and PET-CT
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 30 people
- Sponsor
- Gert Meijer
Prostate Cancer
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Background: The immune system is the cells and organs in the body that recognize and fight infection and cancer. The prostate specific antigen (PSA)/TRICOM (PROSTVAC) vaccine might teach the immune system to find and kill certain…
- Trial name
- NCT02933255
- Testing
- PROSTVAC-V/F, Nivolumab, Prostatectomy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
The study will evaluate the clinical activity of sitravatinib in combination with nivolumab in patients with locally-advanced clear cell renal cell carcinoma (ccRCC) in the neoadjuvant setting prior to nephrectomy.
- Trial name
- NCT03680521
- Testing
- Sitravatinib, Nivolumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mirati Therapeutics Inc.
Fasting Mimicking Diet, Breast Cancer
DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer
Preclinical studies provide strong support for the concept that fasting evokes resistance to multiple forms of stress. Fasting reduces plasma levels of growth factors and modulates intracellular nutrient sensing systems, thereby…
- Conditions
- Fasting Mimicking Diet, Breast Cancer, Neoadjuvant Chemotherapy, Pathological Complete Response
- Trial name
- DIRECT (NCT02126449)
- Testing
- Fasting mimicking diet
- Where
- 15 sites in Netherlands
- Volunteers
- 131 people
- Sponsor
- Leiden University Medical Center
Bladder Cancer
Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
Study participants will have been diagnosed with bladder cancer that has invaded the muscle wall of the bladder. Surgery is used to remove cancer when it is in the muscle of the bladder.
- Trial name
- NCT00585689
- Testing
- ABI-007, Carboplatin, Gemcitabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Michigan Rogel Cancer Center
Adenocarcinoma of the Prostate
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
The area around a tumor ("pre-metastatic niche") may be an area to which cancer cells are attracted. The study doctor will take blood and tumor samples to look for certain features linked with response to treatment so that they…
- Trial name
- NCT01832259
- Testing
- Pazopanib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Utah
Rectal Cancer Patients
Impact Of Metformin In Rectal Cancer Patients
Design: Prospective, randomized controlled clinical trial Setting: at Minia University Hospital and Minia Oncology Institute. Condition: Colorectal cancer.
- Trial name
- NCT06728982
- Testing
- Metformin
- Where
- 2 sites in Egypt
- Volunteers
- 85 people
- Sponsor
- Minia University
Non Small Cell Lung Cancer
Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
The purpose of this multi-center Phase II trial is to examine the impact of pemetrexed/carboplatin in the preoperative treatment of patients with select stage IB, II,and III non-squamous NSCLC.
- Trial name
- NCT00906282
- Testing
- Pemetrexed, Carboplatin
- Where
- 12 sites in United States
- Volunteers
- 46 people
- Sponsor
- SCRI Development Innovations, LLC
Sentinel Lymph Node Biopsy, Neoadjuvant Therapy
Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy
This clinical trial aimed to confirm the effectiveness of sentinel lymph node surgery by determining the lymph node identification rate using multimodal sentinel lymph node marker methods in patients with advanced breast cancer…
- Conditions
- Sentinel Lymph Node Biopsy, Neoadjuvant Therapy, Breast Neoplasm
- Trial name
- NCT06212440
- Testing
- Radioactive Isotope (RI) Mapping, Indocyanine Green Fluorescence (ICG-F) Mapping, Vital Dye Mapping
- Where
- 2 sites in South Korea
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
Head and Neck Squamous Cell Carcinoma
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma
This trial was originally designed and powered to compare biomarker modulation in the neo-adjuvant setting (erlotinib versus erlotinib plus sulindac versus placebo) with clinical response to erlotinib in the adjuvant setting.
- Trial name
- NCT01515137
- Testing
- Erlotinib, Erlotinib plus sulindac
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Pittsburgh
Prostate Cancer
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00005044
- Testing
- Casodex, Eulexin, LHRH agonist
- Where
- 261 sites in United States, Canada
- Volunteers
- 1,579 people
- Sponsor
- Radiation Therapy Oncology Group
Rectal Cancer
A Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer
This is an open-label, randomized phase II study. Patients will be randomly assigned to either FL or TS-1/irinotecan preoperative chemotherapy regimens by stratification.
- Trial name
- NCT01269216
- Testing
- 5-FU with leucovorin, TS-1 with Irinotecan
- Where
- South Korea
- Volunteers
- 136 people
- Sponsor
- Yonsei University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.